TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Non-Hodgkin Lymphoma

2,519 clinical trials

1447 active
/
2519 total (since 2015)
599
Phase 1 Active
1221 total
930
Phase 2 Active
1503 total
163
Phase 3 Active
221 total
23
Phase 4 Active
35 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Roche 17 16 8
Genmab 15 0 3
Merck 14 5 3
AstraZeneca 12 5 4
Bristol-Myers Squibb 10 14 10
Johnson & Johnson 9 9 4
Regeneron 8 1 1
BeiGene 7 15 0
Kite, A Gilead Company 7 9 3
Eli Lilly 7 3 0
Novartis 6 7 8
Loxo Oncology, Inc. 6 1 0
Beijing InnoCare Pharma Tech Co., Ltd. 6 1 0
BeOne Medicines 6 0 0
Ono Pharmaceutical Co. Ltd 6 0 0
NCT03701282 ACTIVE NOT RECRUITING
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) n=720
NCT03737981 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) n=465
NCT03984448 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI) n=363
NCT03914625 ACTIVE NOT RECRUITING
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI) n=6,720
NCT07188558 RECRUITING
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma, Inc. n=400
NCT04269902 RECRUITING
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI) n=247
NCT06943872 RECRUITING
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines n=630
NCT02443077 ACTIVE NOT RECRUITING
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI) n=94
NCT05976763 RECRUITING
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology n=421
NCT06337318 RECRUITING
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
National Cancer Institute (NCI) n=600
NCT04628494 ACTIVE NOT RECRUITING
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Genmab n=484
NCT07226752 ACTIVE NOT RECRUITING
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Genmab n=72
NCT05605899 RECRUITING
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Kite, A Gilead Company n=300
NCT06084936 RECRUITING
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Hoffmann-La Roche n=182
NCT06191744 RECRUITING
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Genmab n=1,095
NCT06508658 RECRUITING
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Genmab n=360
NCT04224493 RECRUITING
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. n=612
NCT03267433 ACTIVE NOT RECRUITING
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ECOG-ACRIN Cancer Research Group n=689
NCT05139017 RECRUITING
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Merck Sharp & Dohme LLC n=290
NCT06717347 RECRUITING
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Merck Sharp & Dohme LLC n=1,046
NCT06136559 RECRUITING
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Merck Sharp & Dohme LLC n=1,200
NCT07104032 RECRUITING
Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Ono Pharmaceutical Co. Ltd n=132
NCT05947851 RECRUITING
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Merck Sharp & Dohme LLC n=735
NCT07414758 RECRUITING
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine n=68
NCT05602194 RECRUITING
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group n=440
NCT03959085 RECRUITING
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group n=5,951
NCT06973187 RECRUITING
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines n=500
NCT05100862 RECRUITING
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
BeiGene n=780
NCT06742996 RECRUITING
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines n=300
NCT05888493 ACTIVE NOT RECRUITING
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Novartis Pharmaceuticals n=109
NCT03480360 ACTIVE NOT RECRUITING
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center n=21
NCT02972840 ACTIVE NOT RECRUITING
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV n=635
NCT06765109 RECRUITING
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Nuvalent Inc. n=450
NCT06549595 RECRUITING
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
AstraZeneca n=1,015
NCT04094311 RECRUITING
Study of Out of Specification for Tisagenlecleucel
Novartis Pharmaceuticals n=200
NCT05254743 RECRUITING
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc. n=662
NCT07029217 RECRUITING
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Memorial Sloan Kettering Cancer Center n=375
NCT07215585 RECRUITING
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
AstraZeneca n=420
NCT07409428 NOT YET RECRUITING
A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL
Hutchmed n=240
NCT06356129 ACTIVE NOT RECRUITING
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Celgene n=850
NCT07402876 RECRUITING
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics, Inc. n=20
NCT06522737 RECRUITING
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
SecuraBio n=124
NCT05171647 ACTIVE NOT RECRUITING
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche n=208
NCT03274492 ACTIVE NOT RECRUITING
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche n=1,000
NCT06230224 RECRUITING
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Regeneron Pharmaceuticals n=216
NCT06097364 ACTIVE NOT RECRUITING
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Regeneron Pharmaceuticals n=733
NCT07377578 RECRUITING
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD. n=394
NCT06149286 RECRUITING
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Regeneron Pharmaceuticals n=470
NCT06091865 ACTIVE NOT RECRUITING
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals n=904
NCT05700448 NOT YET RECRUITING
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals n=150
NCT07389616 RECRUITING
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine n=40
NCT04712097 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Hoffmann-La Roche n=478
NCT04965493 ACTIVE NOT RECRUITING
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Loxo Oncology, Inc. n=600
NCT07355283 NOT YET RECRUITING
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. n=198
NCT04384484 ACTIVE NOT RECRUITING
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A. n=440
NCT05023980 ACTIVE NOT RECRUITING
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc. n=309
NCT07348575 ENROLLING BY INVITATION
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Second Affiliated Hospital of Nanchang University n=80
NCT07342478 NOT YET RECRUITING
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc n=306
NCT05735834 ACTIVE NOT RECRUITING
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
International Extranodal Lymphoma Study Group (IELSG) n=122
NCT05006482 RECRUITING
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
University of Rochester n=668
NCT06776952 RECRUITING
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Evopoint Biosciences Inc. n=120
NCT04408638 ACTIVE NOT RECRUITING
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche n=270
NCT06970743 RECRUITING
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
BeOne Medicines n=150
NCT03570892 ACTIVE NOT RECRUITING
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Novartis Pharmaceuticals n=331
NCT06220032 RECRUITING
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Stichting Hemato-Oncologie voor Volwassenen Nederland n=324
NCT07072585 NOT YET RECRUITING
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group n=1,708
NCT04529772 ACTIVE NOT RECRUITING
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Acerta Pharma BV n=611
NCT05929222 RECRUITING
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Fondazione Italiana Linfomi - ETS n=190
NCT07300514 NOT YET RECRUITING
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Fudan University n=136
NCT04680052 ACTIVE NOT RECRUITING
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Incyte Corporation n=654
NCT06006117 RECRUITING
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation n=260
NCT04404283 ACTIVE NOT RECRUITING
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Seagen, a wholly owned subsidiary of Pfizer n=238
NCT06047080 ACTIVE NOT RECRUITING
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Hoffmann-La Roche n=1,130
NCT05645107 RECRUITING
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics LLC n=386
NCT05429268 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Incyte Corporation n=82
NCT03117751 ACTIVE NOT RECRUITING
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital n=790
NCT06911502 RECRUITING
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene n=400
NCT07084662 RECRUITING
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Sun Yat-sen University n=80
NCT05770037 RECRUITING
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Cancer Research UK n=30
NCT07234162 RECRUITING
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Dizal Pharmaceuticals n=218
NCT06929624 RECRUITING
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=280
NCT04759586 ACTIVE NOT RECRUITING
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
National Cancer Institute (NCI) n=244
NCT06470451 RECRUITING
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Soligenix n=80
NCT07220187 NOT YET RECRUITING
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
SWOG Cancer Research Network n=102
NCT06072131 RECRUITING
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Acrotech Biopharma Inc. n=504
NCT04459416 ACTIVE NOT RECRUITING
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center n=299
NCT05371093 ACTIVE NOT RECRUITING
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company n=231
NCT03823534 RECRUITING
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University n=60
NCT07202065 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Monash University n=900
NCT07202078 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Monash University n=900
NCT07202091 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Monash University n=900
NCT03057054 ACTIVE NOT RECRUITING
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Children's Oncology Group n=173
NCT05556720 ACTIVE NOT RECRUITING
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Monash University n=960
NCT04442022 RECRUITING
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc n=501
NCT06091254 ACTIVE NOT RECRUITING
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Follicular Lymphoma
Regeneron Pharmaceuticals n=462
NCT04833114 ACTIVE NOT RECRUITING
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
GWT-TUD GmbH n=306
NCT04002297 ACTIVE NOT RECRUITING
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
BeiGene n=510
NCT07187960 NOT YET RECRUITING
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. n=228
NCT07185373 NOT YET RECRUITING
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
Huashan Hospital n=215
NCT07011056 RECRUITING
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd n=390
NCT07178457 NOT YET RECRUITING
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
Assistance Publique - Hôpitaux de Paris n=84
NCT06947967 RECRUITING
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Chipscreen Biosciences, Ltd. n=224
NCT06082102 RECRUITING
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. n=324
NCT07168980 RECRUITING
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Children's Cancer Group, China n=87
NCT04824092 ACTIVE NOT RECRUITING
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Incyte Corporation n=899
NCT05058404 ACTIVE NOT RECRUITING
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
Fondazione Italiana Linfomi - ETS n=605
NCT05409066 ACTIVE NOT RECRUITING
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Genmab n=549
NCT04212013 ACTIVE NOT RECRUITING
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center n=23
NCT05624554 ACTIVE NOT RECRUITING
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Merck Sharp & Dohme LLC n=300
NCT04668690 ACTIVE NOT RECRUITING
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=193
NCT04662255 ACTIVE NOT RECRUITING
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Loxo Oncology, Inc. n=500
NCT06953739 NOT YET RECRUITING
A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
The First Affiliated Hospital with Nanjing Medical University n=60
NCT04931368 RECRUITING
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
Klinikum Stuttgart n=326
NCT04666038 ACTIVE NOT RECRUITING
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc. n=238
NCT06561048 RECRUITING
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc. n=150
NCT03206671 ACTIVE NOT RECRUITING
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
University Hospital Muenster n=650
NCT04043494 RECRUITING
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
University Hospital Muenster n=683
NCT04365036 RECRUITING
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
Sun Yat-sen University n=207
NCT03336333 ACTIVE NOT RECRUITING
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
BeiGene n=590
NCT03593018 ACTIVE NOT RECRUITING
Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL
The Lymphoma Academic Research Organisation n=86
NCT06830421 RECRUITING
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
University Hospital Freiburg n=340
NCT02845882 ACTIVE NOT RECRUITING
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China n=150
NCT02405676 ACTIVE NOT RECRUITING
BNHL-2015 for Children or Adolescents in China
Children's Cancer Group, China n=200
NCT05681260 RECRUITING
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children with Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
Children's Cancer Group, China n=200
NCT04881838 RECRUITING
CCCG-ALCL-2020 for Chinese Children and Adolescents with Newly Diagnosed High-risk ALCL
Children's Cancer Group, China n=172
NCT06792253 RECRUITING
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc n=416
NCT05578976 ACTIVE NOT RECRUITING
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab n=900
NCT06756152 RECRUITING
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=50
NCT06363994 RECRUITING
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
InnoCare Pharma Inc. n=476
NCT06724237 NOT YET RECRUITING
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Eastern Cooperative Oncology Group n=294
NCT05045664 RECRUITING
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
Heidelberg University n=100
NCT04231448 ACTIVE NOT RECRUITING
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Chipscreen Biosciences, Ltd. n=423
NCT04834024 RECRUITING
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Beijing Mabworks Biotech Co., Ltd. n=168
NCT06284122 RECRUITING
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
The Lymphoma Academic Research Organisation n=790
NCT04332822 RECRUITING
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Nordic Lymphoma Group n=300
NCT06573645 NOT YET RECRUITING
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Xia Yi n=428
NCT06475820 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT06548347 NOT YET RECRUITING
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd. n=606
NCT06522555 RECRUITING
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Ruijin Hospital n=100
NCT06521255 RECRUITING
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. n=244
NCT06510530 NOT YET RECRUITING
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Bnai Zion Medical Center n=60
NCT06496308 RECRUITING
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Ruijin Hospital n=78
NCT03703375 ACTIVE NOT RECRUITING
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Celgene n=93
NCT06434467 NOT YET RECRUITING
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=83
NCT06355401 NOT YET RECRUITING
Maintenance Hormonal Therapy and DLBCL
Sohag University n=100
NCT05075460 RECRUITING
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
Peking Union Medical College Hospital n=107
NCT03213977 ACTIVE NOT RECRUITING
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Fujian Medical University n=475
NCT06313996 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company n=300
NCT06255795 NOT YET RECRUITING
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
Ruijin Hospital n=142
NCT06188676 RECRUITING
Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
National Research Center for Hematology, Russia n=100
NCT05328258 RECRUITING
Use of GnRHa During Chemotherapy for Fertility Protection
Kenny Rodriguez-Wallberg n=500
NCT05515029 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=56
NCT05820841 RECRUITING
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
Universität des Saarlandes n=330
NCT05931263 RECRUITING
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
The First Affiliated Hospital with Nanjing Medical University n=104
NCT05351346 RECRUITING
Genotype-guided Treatment in DLBCL
Ruijin Hospital n=1,100
NCT05775705 NOT YET RECRUITING
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital n=25
NCT05678933 ENROLLING BY INVITATION
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
Tianjin Medical University Cancer Institute and Hospital n=200
NCT05051891 RECRUITING
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. n=356
NCT04442412 RECRUITING
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
Fondazione Italiana Linfomi - ETS n=430
NCT05205902 NOT YET RECRUITING
TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides
Assistance Publique - Hôpitaux de Paris n=78
NCT04670029 RECRUITING
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
Weprom n=186
NCT03647072 RECRUITING
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
Sherief Abd-Elsalam n=60
NCT02858258 RECRUITING
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Prof. Dr. M. Dreyling (co-chairman) n=870
NCT04799275 SUSPENDED
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI) n=422
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT04214444 COMPLETED
Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab
University Hospital, Tours n=26
NCT04182204 COMPLETED
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche n=270
NCT02881086 COMPLETED
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University n=1,023
NCT03391466 COMPLETED
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Kite, A Gilead Company n=359
NCT02367040 COMPLETED
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Bayer n=458
NCT06125028 TERMINATED
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
Pentixapharm AG n=13
NCT03575351 COMPLETED
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
Celgene n=184
NCT02947347 COMPLETED
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC. n=445
NCT03112174 COMPLETED
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Pharmacyclics LLC. n=366
NCT02763319 COMPLETED
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Incyte Corporation n=453
NCT02320292 TERMINATED
Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Mayo Clinic n=20
NCT03734016 COMPLETED
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
BeiGene n=652
NCT05664217 TERMINATED
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Therapeutics n=15
NCT03366272 COMPLETED
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
Universität des Saarlandes n=348
NCT03263026 COMPLETED
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Denovo Biopharma LLC n=256
NCT02626455 TERMINATED
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Bayer n=551
NCT02406092 COMPLETED
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche n=139
NCT04745832 TERMINATED
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc. n=82
NCT03078855 COMPLETED
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Jonathan Friedberg n=211
NCT03406156 COMPLETED
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie n=120
NCT03801525 TERMINATED
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
TG Therapeutics, Inc. n=277
NCT03959241 COMPLETED
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Medical College of Wisconsin n=431
NCT03976102 COMPLETED
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
Dr. Reddy's Laboratories Limited n=317
NCT04361279 COMPLETED
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
Shanghai Institute Of Biological Products n=421
NCT02369016 COMPLETED
Phase III Copanlisib in Rituximab-refractory iNHL
Bayer n=25
NCT02617485 COMPLETED
MabionCD20 Compared to MabThera in Lymphoma Patients
Mabion SA n=143
NCT02536300 TERMINATED
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Gilead Sciences n=96
NCT02285062 COMPLETED
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Celgene n=570
NCT05431179 WITHDRAWN
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
NCT03372837 COMPLETED
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals n=40
NCT02942173 COMPLETED
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT04236141 TERMINATED
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
Hoffmann-La Roche n=42
NCT04021082 WITHDRAWN
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Portola Pharmaceuticals
NCT02303119 COMPLETED
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
The Lymphoma Academic Research Organisation n=221
NCT02703272 TERMINATED
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC n=72
NCT02811783 TERMINATED
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Elorac, Inc. n=59
NCT02747043 COMPLETED
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Amgen n=256
NCT02793583 TERMINATED
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
TG Therapeutics, Inc. n=710
NCT04796922 WITHDRAWN
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
NCT04849715 WITHDRAWN
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Incyte Corporation
NCT02448381 COMPLETED
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Soligenix n=169
NCT02369653 COMPLETED
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Bristol-Myers Squibb n=512
NCT02260804 COMPLETED
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Celltrion n=258
NCT02576275 WITHDRAWN
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
SecuraBio
NCT04671420 WITHDRAWN
Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.
Shanghai Henlius Biotech
NCT02951156 TERMINATED
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Pfizer n=29
NCT02809053 COMPLETED
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Archigen Biotech Limited n=315
NCT03242902 COMPLETED
To Decrease Fatigue With Light Therapy
The Netherlands Cancer Institute n=166
NCT02867566 COMPLETED
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
Innovent Biologics (Suzhou) Co. Ltd. n=420
NCT03670901 TERMINATED
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
JHL Biotech, Inc. n=8
NCT03349333 COMPLETED
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Mundipharma (China) Pharmaceutical Co. Ltd n=85
NCT03355768 WITHDRAWN
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Jennifer Amengual
NCT02359162 TERMINATED
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
Sun Yat-sen University n=50
NCT02366663 TERMINATED
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
City of Hope Medical Center n=3
NCT02417129 TERMINATED
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Boehringer Ingelheim n=2
NCT02735876 WITHDRAWN
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Acerta Pharma BV

Data: ClinicalTrials.gov